scPharmaceuticals, Inc. clinical trials
Acquired by Mannkind Corporation, Oct 7, 2025 · source ↗
The registry lists 9 studies whose lead sponsor is scPharmaceuticals, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 30, 2026.
Before and after it joined Mannkind Corporation
- First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation
- 9
- First submitted after scPharmaceuticals, Inc. became part of Mannkind Corporation
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- scPharmaceuticals, Inc.9 studies
Something wrong with this grouping? Tell us on the Mannkind Corporation page.
Studies
Recruiting first, then most recently updated. Showing 9 of 9. All Mannkind Corporation studies →
- Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy VolunteersCompletedNCT06167707Phase 1
Sponsor listed in the registry: scPharmaceuticals, Inc. · First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation
- Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot StudyCompletedNCT04593823Phase 2
Sponsor listed in the registry: scPharmaceuticals, Inc. · First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation
- Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart FailureCompletedNCT03458325Phase 3
Sponsor listed in the registry: scPharmaceuticals, Inc. · First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation
- Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart FailureCompletedNCT02329834Phase 2/3
Sponsor listed in the registry: scPharmaceuticals, Inc. · First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation
- An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin TolerabilityCompletedNCT04161482Phase 1
Sponsor listed in the registry: scPharmaceuticals, Inc. · First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation
- Product Design Clinical Performance Study of sc2Wear Furosemide Combination ProductCompletedNCT02804282Phase 3
Sponsor listed in the registry: scPharmaceuticals, Inc. · First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation
- Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral AdministrationCompletedNCT02350725Phase 1/2
Sponsor listed in the registry: scPharmaceuticals, Inc. · First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation
- Pilot Study for First Clinical Use of sc2Wear Furosemide Combination ProductCompletedNCT02804035Phase 2
Sponsor listed in the registry: scPharmaceuticals, Inc. · First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation
- Crossover Study to Compare the Pharmacokinetics of Subcutaneous and Intravenous Ceftriaxone AdministrationCompletedNCT02561442Phase 2/3
Sponsor listed in the registry: scPharmaceuticals, Inc. · First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation